Gland Pharma Ltd — Profit & Loss Statement

₹1696.10

+0.56%

Gland Pharma Ltd Profit & Loss Statement (Annual)

Metric	2025	2024	2023	2022
Tax Effect Of Unusual Items	0.78 Cr	-1.23 Cr	-11.85 Cr	1.01 Cr
Tax Rate For Calcs	0.34	0.32	0.26	0.25
Normalized EBITDA	1.48K Cr	1.50K Cr	1.25K Cr	1.73K Cr
Total Unusual Items	2.27 Cr	-3.88 Cr	-45.70 Cr	4.01 Cr
Total Unusual Items Excluding Goodwill	2.27 Cr	-3.88 Cr	-45.70 Cr	4.01 Cr
Net Income From Continuing Operation Net Minority Interest	698.53 Cr	772.46 Cr	781.04 Cr	1.21K Cr
Reconciled Depreciation	377.87 Cr	344.57 Cr	146.74 Cr	110.30 Cr
Reconciled Cost Of Revenue	2.09K Cr	2.17K Cr	1.69K Cr	2.11K Cr
EBITDA	1.48K Cr	1.50K Cr	1.21K Cr	1.73K Cr
EBIT	1.10K Cr	1.15K Cr	1.06K Cr	1.62K Cr
Net Interest Income	162.28 Cr	124.41 Cr	171.97 Cr	133.40 Cr
Interest Expense	37.40 Cr	21.79 Cr	6.29 Cr	3.40 Cr
Interest Income	204.28 Cr	150.60 Cr	179.42 Cr	138.65 Cr
Normalized Income	697.03 Cr	775.11 Cr	814.89 Cr	1.21K Cr
Net Income From Continuing And Discontinued Operation	698.53 Cr	772.46 Cr	781.04 Cr	1.21K Cr
Total Expenses	4.69K Cr	4.65K Cr	2.72K Cr	2.98K Cr
Rent Expense Supplemental	10.43 Cr	9.92 Cr	1.42 Cr	1.12 Cr
Diluted Average Shares	16.47 Cr	16.47 Cr	16.47 Cr	16.45 Cr
Basic Average Shares	16.47 Cr	16.47 Cr	16.46 Cr	16.42 Cr
Diluted EPS	42.40	46.89	47.43	73.64
Basic EPS	42.40	46.90	47.44	73.81
Diluted NI Availto Com Stockholders	698.53 Cr	772.46 Cr	781.04 Cr	1.21K Cr
Net Income Common Stockholders	698.53 Cr	772.46 Cr	781.04 Cr	1.21K Cr
Otherunder Preferred Stock Dividend	0.00	0.00	0.00	0.00
Net Income	698.53 Cr	772.46 Cr	781.04 Cr	1.21K Cr
Minority Interests	0.00	0.00	0.00	0.00
Net Income Including Noncontrolling Interests	698.53 Cr	772.46 Cr	781.04 Cr	1.21K Cr
Net Income Continuous Operations	698.53 Cr	772.46 Cr	781.04 Cr	1.21K Cr
Tax Provision	364.13 Cr	360.08 Cr	273.54 Cr	406.89 Cr
Pretax Income	1.06K Cr	1.13K Cr	1.05K Cr	1.62K Cr
Other Non Operating Income Expenses	7.84 Cr	5.32 Cr	1.05 Cr	1.55 Cr
Special Income Charges	1.05 Cr	-4.23 Cr	-48.55 Cr	-0.48 Cr
Other Special Charges	-6.72 Cr	-3.36 Cr	40.01 Cr	0.13 Cr
Write Off	5.68 Cr	7.58 Cr	8.54 Cr	0.34 Cr
Net Non Operating Interest Income Expense	162.28 Cr	124.41 Cr	171.97 Cr	133.40 Cr
Total Other Finance Cost	4.60 Cr	4.41 Cr	1.16 Cr	1.84 Cr
Interest Expense Non Operating	37.40 Cr	21.79 Cr	6.29 Cr	3.40 Cr
Interest Income Non Operating	204.28 Cr	150.60 Cr	179.42 Cr	138.65 Cr
Operating Income	890.00 Cr	996.09 Cr	870.11 Cr	1.40K Cr
Operating Expense	2.60K Cr	2.47K Cr	1.04K Cr	874.55 Cr
Other Operating Expenses	665.09 Cr	682.22 Cr	385.18 Cr	327.34 Cr
Depreciation And Amortization In Income Statement	377.87 Cr	344.57 Cr	146.74 Cr	110.30 Cr
Amortization	18.56 Cr	18.69 Cr	0.87 Cr	0.45 Cr
Depreciation Income Statement	359.31 Cr	325.88 Cr	145.86 Cr	109.85 Cr
Research And Development	33.28 Cr	32.03 Cr	40.38 Cr	42.66 Cr
Selling General And Administration	141.12 Cr	169.91 Cr	75.56 Cr	71.14 Cr
Selling And Marketing Expense	27.48 Cr	37.46 Cr	27.03 Cr	40.98 Cr
General And Administrative Expense	113.64 Cr	132.44 Cr	48.53 Cr	30.16 Cr
Rent And Landing Fees	10.43 Cr	9.92 Cr	1.42 Cr	1.12 Cr
Gross Profit	3.49K Cr	3.47K Cr	1.91K Cr	2.27K Cr
Cost Of Revenue	2.09K Cr	2.17K Cr	1.69K Cr	2.11K Cr
Total Revenue	5.58K Cr	5.64K Cr	3.59K Cr	4.38K Cr
Operating Revenue	5.58K Cr	5.64K Cr	3.59K Cr	4.38K Cr

All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.

More on Gland Pharma Ltd

Overview Financials PE History Shareholding Quarterly Balance Sheet P&L Cash Flow Pharmaceuticals Stocks Screener

Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.